News from pharmabcine A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Dec 12, 2022, 08:00 ET PharmAbcine Announces Collaboration Agreement with MSD to Evaluate Anti-VISTA Antibody PMC-309 in Combination with KEYTRUDA® (pembrolizumab)

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced ...

Dec 08, 2022, 08:00 ET PharmAbcine to Participate in the 41th Annual J.P. Morgan Healthcare Conference and Biotech Showcase™ 2023 during JPM Week

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced ...

Oct 24, 2022, 08:00 ET PharmAbcine to participate in Jefferies 2022 London Healthcare Conference

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced ...

Oct 17, 2022, 08:00 ET PharmAbcine Announces Poster Presentations on Its anti-VISTA Antibody Candidate at SITC 2022

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the...

Sep 26, 2022, 08:00 ET PharmAbcine to Participate in BIO-Europe 2022

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced ...

May 11, 2022, 08:00 ET PharmAbcine to participate in Jefferies Global Healthcare Conference and BIO International Convention

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced ...

Apr 26, 2022, 08:30 ET PharmAbcine Announces Positive Results for Its Novel TIE2-Activating Antibody in GLP Toxicology Study

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced ...

Apr 26, 2022, 08:00 ET PharmAbcine Strengthens Scientific Advisory Board with a World-Renowned Expert in Ophthalmology

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced ...

Apr 11, 2022, 08:00 ET PharmAbcine Presents Updated Preclinical Data of Its Anti-VISTA Antibody Candidate at AACR 2022

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced ...

Mar 08, 2022, 16:30 ET PharmAbcine to Present Updated Data of Its Anti-VISTA Antibody Candidate at AACR 2022

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the...

Feb 25, 2022, 08:00 ET PharmAbcine Announces Last Patient Last Visit in its Phase Ib mTNBC Combination Trial

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced ...

Dec 27, 2021, 08:00 ET PharmAbcine Announces First Patient Enrolled and Dosed in the Phase II Clinical Trial for the Treatment of mTNBC

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, today...

Dec 06, 2021, 08:00 ET PharmAbcine to participate in J.P. Morgan Healthcare Conference and Biotech Showcase during "J.P. Morgan Week 2022"

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of fully human antibody therapeutics, announced...

Oct 19, 2021, 08:00 ET PharmAbcine Announces Patent Grant in Australia for Its Anti-VISTA Antibody

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced ...

Sep 20, 2021, 08:00 ET PharmAbcine to Participate in BIO-Europe 2021

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced ...

Sep 13, 2021, 08:00 ET PharmAbcine to Participate in ACCESS CHINA Biotech Forum

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced ...

Sep 09, 2021, 08:00 ET PharmAbcine Announces Joint Patent Application with MSD for the Treatment of Cancer

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, today...

Sep 03, 2021, 08:00 ET PharmAbcine Receives HREC Clearance for Phase II Trial of Olinvacimab and Pembrolizumab in mTNBC

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the...

Aug 23, 2021, 08:00 ET PharmAbcine to Participate in H.C. Wainright 23rd Annual Global Investment Conference

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced ...

Aug 19, 2021, 08:00 ET PharmAbcine Announces Submission of PCT for an Anti-ANG2 Antibody for the Treatment of Ocular Diseases

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, today...

Aug 17, 2021, 08:00 ET PharmAbcine to Participate in Biotechgate Digital Partnering

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced ...

Jul 26, 2021, 08:00 ET PharmAbcine to Present at H.C Wainwright Ophthalmology Virtual Conference

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced ...

Jun 02, 2021, 08:00 ET PharmAbcine to Present at the BIO Digital International Convention 2021

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the...

May 10, 2021, 08:00 ET PharmAbcine Announces Encouraging Non-clinical Data of PMC-403 at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the...

Apr 26, 2021, 08:00 ET PharmAbcine to Present at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the...